Incannex Healthcare Limited Sponsored ADR (IXHL)
NASDAQ:IXHL
Want to see IXHL full AI Analyst Report?
Top Page
Incannex Healthcare Limited Sponsored ADR
(NASDAQ:IXHL)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.50
▲(1053.85% Upside)
Action:ReiteratedDate:04/23/26
The score is held back primarily by weak financial performance—large ongoing losses and negative free cash flow—despite a low-leverage balance sheet. Technicals also remain mixed-to-bearish with the stock below key longer-term moving averages and a negative MACD. Offsetting these factors, corporate events are constructive (improved cash position, buyback reactivation, Nasdaq compliance, and pipeline progress), but valuation support is limited by the negative P/E and lack of dividend yield data.
Positive Factors
Strong balance sheet and cash runway
A cash balance of roughly $75M and no debt materially reduces near-term refinancing pressure and gives management flexibility to fund clinical programs. This durable liquidity supports completing mid-stage trials and selective capital allocation without immediate reliance on dilutive financing.
Negative Factors
Persistent negative operating and free cash flow
Consistent negative operating and free cash flow—approximately -$12.5M in 2025—signals ongoing cash burn. Even with current cash, sustained losses mean continued funding needs to progress trials; this structural cash consumption limits optionality and elevates execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet and cash runway
A cash balance of roughly $75M and no debt materially reduces near-term refinancing pressure and gives management flexibility to fund clinical programs. This durable liquidity supports completing mid-stage trials and selective capital allocation without immediate reliance on dilutive financing.
Read all positive factors
Incannex Healthcare Limited Sponsored ADR (IXHL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$68.61M
Dividend YieldN/A
Average Volume (3M)661.87K
Price to Earnings (P/E)―
Beta (1Y)3.74
Revenue Growth-100.00%
EPS Growth46.50%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.20
Shares Outstanding13,973,663
10 Day Avg. Volume497,474
30 Day Avg. Volume661,868
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)86.40
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.18
Enterprise Value/Revenue-184.64
Enterprise Value/Gross Profit-184.64
Enterprise Value/Ebitda0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)$700.00K
Incannex Healthcare Limited Sponsored ADR Business Overview & Revenue Model
Company Description
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, w...
How the Company Makes Money
null...
Incannex Healthcare Limited Sponsored ADR Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Sep 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.62K | 86.00K | ― | 0.00 | 0.00 | 1.43M |
| Gross Profit | 66.62K | 86.00K | ― | 0.00 | -4.36K | 740.54K |
| EBITDA | -45.51M | -48.09M | -27.70M | -13.55M | -10.16M | -8.57M |
| Net Income | -42.09M | -46.88M | -27.63M | -48.81M | -10.25M | -8.54M |
Balance Sheet | ||||||
| Total Assets | 75.01M | 20.45M | 17.05M | 23.78M | 26.15M | 7.00M |
| Cash, Cash Equivalents and Short-Term Investments | 68.90M | 15.04M | 5.86M | 22.12M | 25.80M | 6.84M |
| Total Debt | 210.00K | 258.00K | 373.00K | 521.00K | 0.00 | 0.00 |
| Total Liabilities | 1.71M | 7.06M | 5.83M | 2.96M | 1.39M | 566.17K |
| Stockholders Equity | 73.41M | 13.39M | 11.22M | 20.82M | 24.76M | 6.44M |
Cash Flow | ||||||
| Free Cash Flow | -10.24M | -12.52M | -16.12M | -11.06M | -8.84M | -5.18M |
| Operating Cash Flow | -10.23M | -12.51M | -15.85M | -10.75M | -8.84M | -5.18M |
| Investing Cash Flow | 20.00K | -8.00K | -277.00K | -316.00K | 0.00 | 22.00K |
| Financing Cash Flow | 84.52M | 21.40M | 0.00 | 8.18M | 28.33M | 9.30M |
Incannex Healthcare Limited Sponsored ADR Technical Analysis
Neutral
0.39
Price Trends
4.74
Negative
8.03
Negative
11.27
Negative
Market Momentum
-0.30
Negative
49.38
Neutral
90.14
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IXHL, the sentiment is Neutral. The current price of 0.39 is below the 20-day moving average (MA) of 3.13, below the 50-day MA of 4.74, and below the 200-day MA of 11.27, indicating a neutral trend. The MACD of -0.30 indicates Negative momentum. The RSI at 49.38 is Neutral, neither overbought nor oversold. The STOCH value of 90.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IXHL.
Incannex Healthcare Limited Sponsored ADR Risk Analysis
Incannex Healthcare Limited Sponsored ADR disclosed 68 risk factors in its most recent earnings report. Incannex Healthcare Limited Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Incannex Healthcare Limited Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $65.36M | -3.69 | -10.54% | ― | 2.08% | -106.57% | |
59 Neutral | $143.08M | -1.32 | -29.39% | ― | -5.00% | -39.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $819.58M | -4.58 | -27.86% | ― | ― | -9.36% | |
49 Neutral | $68.61M | -4.80 | -199.09% | ― | -100.00% | 46.50% | |
48 Neutral | $142.39M | -37.87 | -46.40% | ― | 10.20% | 35.27% |
* Healthcare Sector Average
IXHL
Incannex Healthcare Limited Sponsored ADR
4.91
1.28
35.30%
ASRT
Assertio Therapeutics
22.20
12.94
139.74%
CPIX
Cumberland Pharmaceuticals
4.37
-0.05
-1.13%
SXTC
China SXT Pharmaceuticals
1.76
-283.24
-99.38%
DERM
Journey Medical Corp
5.21
-1.74
-25.04%
BIOA
BioAge Labs, Inc.
18.46
14.40
354.68%
Incannex Healthcare Limited Sponsored ADR Corporate Events
Business Operations and StrategyProduct-Related Announcements
Incannex Highlights Psilocybin Anxiety Program Amid U.S. Policy Shift
Positive
Apr 22, 2026
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company developing combination therapies for chronic conditions, is advancing three key product candidates targeting obstructive sleep apnea, rheumatoid arthritis and generalized anxiety...
Business Operations and StrategyStock Buyback
Incannex Reactivates Share Buyback, Signaling Valuation Confidence
Positive
Mar 27, 2026
On March 27, 2026, Incannex Healthcare Inc. announced it has reactivated its previously approved share repurchase program, resuming buybacks over the past two trading days after a period of inactivity. The board’s decision signals confidence...
Business Operations and Strategy
Incannex Deepens Sleep Apnea Focus With AASM Partnership
Positive
Mar 25, 2026
On March 25, 2026, Incannex Healthcare Inc., a clinical-stage biopharmaceutical company focused on combination therapies for high-impact chronic conditions, announced a partnership with the American Academy of Sleep Medicine Foundation and entry i...
Business Operations and StrategyStock BuybackFinancial DisclosuresPrivate Placements and Financing
Incannex Healthcare Strengthens Cash Position, Highlights Clinical Pipeline
Positive
Mar 18, 2026
On March 18, 2026, Incannex Healthcare reported that it now holds approximately $75 million in cash and no debt following a financing led by healthcare-focused institutional investors, leaving the company with a negative enterprise value relative ...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Incannex Regains Nasdaq Compliance, Strengthening Pipeline Progress
Positive
Mar 17, 2026
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, is developing oral fixed-dose combination therapies for chronic conditions such as obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder, led by its IHL...
Business Operations and StrategyPrivate Placements and Financing
Incannex Highlights Enhanced Phase 2 Study and Updates
Neutral
Mar 12, 2026
Incannex Healthcare Inc. has mutually agreed with its sales agents Curvature Securities and A.G.P./Alliance Global Partners to terminate, effective March 11, 2026, its at-the-market Sales Agreement under which it had raised approximately $108.4 mi...
Business Operations and StrategyPrivate Placements and Financing
Incannex Healthcare Announces $10 Million Direct Offering
Positive
Mar 12, 2026
On March 12, 2026, Incannex Healthcare Inc. agreed to raise approximately $10 million through a registered direct offering of 2,000,000 shares of common stock or equivalents and accompanying common warrants priced at $5.00 per share-and-warrant un...
Business Operations and StrategyRegulatory Filings and ComplianceStock Split
Incannex Healthcare Announces 1-for-30 Reverse Stock Split
Neutral
Feb 25, 2026
On February 24, 2026, Incannex Healthcare filed a certificate of amendment in Delaware to implement a 1-for-30 reverse stock split of its common stock, effective at 4:01 p.m. Eastern Time on February 26, 2026, with post-split trading on the Nasdaq...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.